COPD and asthma both cause shortness of breath, wheezing, and coughing, but they require different treatments and carry different long-term outlooks. Telling them apart relies on a combination of your medical history, breathing tests, and sometimes blood work or imaging. No single test gives a definitive answer on its own, so doctors piece together several clues.
Why It Matters to Get the Right Diagnosis
Asthma and COPD can look nearly identical on the surface. Both involve narrowed airways and difficulty moving air out of the lungs. But asthma is driven primarily by allergic or immune-related inflammation that comes and goes, while COPD involves progressive, largely irreversible damage from long-term exposure to irritants like cigarette smoke. The medications, monitoring schedules, and goals of treatment differ significantly between the two. Getting the wrong label can mean years on the wrong therapy.
Clinical History: The First Filter
Before any testing, your age, smoking history, and symptom pattern do a lot of the sorting. Asthma most often starts in childhood or early adulthood and is one of the most common chronic illnesses in kids. COPD, by contrast, typically appears in middle age or later, after years of smoking or occupational exposure to dust, chemicals, or fumes.
Symptom triggers also point in different directions. Asthma flare-ups tend to follow exposure to allergens (pollen, mold, dust mites, pet dander) or physical activity. Symptoms often come in episodes, with stretches of feeling perfectly normal in between. COPD symptoms are more constant: a daily cough, persistent mucus production, and gradually worsening breathlessness during routine activities. If you’ve smoked 10 or more pack-years and your breathing problems started after age 40, COPD moves to the top of the list. If you have a personal or family history of allergies, eczema, or hay fever and symptoms that wax and wane, asthma is more likely.
Spirometry: The Core Breathing Test
Spirometry is the single most important diagnostic test for both conditions. You blow as hard and fast as you can into a mouthpiece, and the device measures two key numbers: how much air you can force out in one second (FEV1) and the total volume you can exhale (FVC). The ratio between them reveals whether your airways are obstructed.
For patients 65 and older, a post-bronchodilator FEV1/FVC ratio below 70% is the standard threshold for diagnosing obstructive lung disease, based on the GOLD criteria used worldwide. For younger patients and nonsmokers over 65, doctors compare your ratio to the statistical lower limit of normal for your age, sex, and height, since a fixed 70% cutoff can overdiagnose older adults and underdiagnose younger ones.
An abnormal ratio tells you obstruction exists, but not which disease is causing it. That’s where the next step comes in.
Bronchodilator Reversibility Testing
Right after baseline spirometry, you inhale a fast-acting bronchodilator (a medication that relaxes airway muscles) and repeat the test about 15 minutes later. The question is simple: did your airways open back up?
A “positive” reversibility test in adults means your FEV1 improved by at least 12% and at least 200 mL from the pre-medication reading. That pattern of reversible obstruction is a hallmark of asthma. In COPD, the obstruction persists. Airways may open slightly, but they don’t return to normal because the structural damage from years of inflammation or emphysema can’t be undone with a single dose of medication.
There’s an important gray area, though. Some people with longstanding, poorly controlled asthma develop partially fixed obstruction that doesn’t fully reverse. And some COPD patients do show modest reversibility. A very large response, greater than 400 mL of improvement, strongly suggests asthma features are present even in someone who otherwise looks like a COPD patient.
Exhaled Nitric Oxide (FeNO)
This simple breath test measures a gas produced by inflamed airway cells. You breathe steadily into a device for about 10 seconds, and it reports a number in parts per billion. Higher levels reflect the type of immune-driven inflammation characteristic of asthma.
The usefulness depends on where the cutoff is set. At levels below 20 ppb, the test catches about 79% of asthma cases while correctly ruling it out in 72% of people without asthma. At 40 ppb or above, the test becomes highly specific: if your reading is that high, the odds of having asthma increase roughly sevenfold, though it misses more mild cases at that strict threshold. FeNO levels in COPD without an asthma component tend to be lower, making this test a useful tiebreaker when spirometry alone isn’t clear.
Blood Eosinophils
A standard blood draw can measure eosinophils, a type of white blood cell involved in allergic inflammation. Elevated eosinophil counts are a classic marker of asthma. Interestingly, about 56% of COPD patients also have blood eosinophil levels at or above 150 cells per microliter, so a mildly elevated count doesn’t automatically mean asthma. But very high counts in someone with airflow obstruction tilt the diagnosis toward asthma or suggest an overlap between the two conditions. Eosinophil levels also help guide treatment decisions, since certain inhaled medications work best when this type of inflammation is present.
Lung Diffusion Testing
This test, sometimes called DLCO, measures how efficiently oxygen passes from your lungs into your bloodstream. You breathe in a tiny, harmless amount of carbon monoxide, hold your breath briefly, then exhale. The amount your lungs absorb reveals how intact the gas-exchanging tissue is.
In COPD, particularly the emphysema type, the walls between air sacs are destroyed. That means less surface area for gas exchange, so diffusion capacity drops. In asthma, the air sacs are typically healthy. Diffusion capacity is normal or even slightly elevated. This distinction makes the test especially helpful when you need to know whether emphysema is part of the picture.
CT Imaging
A CT scan of the chest isn’t always necessary, but it can provide direct visual evidence when the diagnosis is uncertain. In COPD, scans often show emphysema (areas of destroyed lung tissue that appear as dark patches), hyperinflation, and sometimes fluid-filled sacs called bullae. Research has identified emphysema on CT as one of the most important features for distinguishing COPD from asthma. Airway features matter too: total airway count and airway wall measurements differ between the two diseases and can be analyzed with increasing precision.
In asthma, CT scans may show thickened bronchial walls and air trapping during exhalation, but the lung tissue itself usually looks normal. If your scan shows significant emphysema, COPD is almost certainly part of your diagnosis regardless of other test results.
When It Looks Like Both: Asthma-COPD Overlap
Some people genuinely have features of both diseases at the same time. This is called asthma-COPD overlap, or ACO, and it affects a meaningful subset of patients with chronic airway disease. The diagnosis requires a significant smoking or biomass fuel exposure history. A never-smoker with asthma who develops some fixed obstruction over time isn’t classified as ACO; they have remodeled asthma.
Several findings point toward overlap. Blood and sputum eosinophil counts tend to be significantly higher in ACO than in straightforward COPD. A very positive bronchodilator response (greater than 400 mL improvement in FEV1) in someone with otherwise typical COPD suggests asthma features are present. CT imaging in ACO patients shows more emphysema than in pure asthma, often concentrated in the upper portions of the lungs. Identifying overlap matters because these patients generally respond well to inhaled corticosteroids, which are a cornerstone of asthma treatment but less consistently helpful in COPD alone.
Putting the Pieces Together
No single test draws a clean line between asthma and COPD. Diagnosis works by layering evidence. A 25-year-old nonsmoker with episodic wheezing, a strong family history of allergies, full reversibility on spirometry, and a FeNO of 45 ppb has asthma. A 60-year-old with a 30-pack-year smoking history, daily breathlessness, fixed obstruction on spirometry, low diffusion capacity, and emphysema on CT has COPD. Most cases are this straightforward.
The harder calls come when history points one direction and test results point another, or when features of both diseases coexist. In those situations, the combination of reversibility testing, eosinophil counts, FeNO, and imaging usually provides enough information to guide the right treatment plan. If your initial evaluation leaves questions unanswered, repeat spirometry over time can also help: asthma tends to show variable results from visit to visit, while COPD shows a steady or declining trajectory.